Lexaria Bioscience Corp.

LEXX

US52886N4060

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 10:30:00 03/07/2024 pm IST			5-day change	1st Jan Change
2.64 ^USD	+0.76%		+1.93%	+111.20%

18/06	Lexaria Bioscience Hires Contract Research Organization For 12-week Study	MT
18/06	Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study	CI

Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2020

January 15, 2021 at 02:27 am IST

Lexaria Bioscience Corp. announced earnings results for the first quarter ended November 30, 2020. For the first quarter, the company announced sales was USD 295,656 compared to USD 10,332 a year ago. Net loss was USD 696,028 compared to USD 907,312 a year ago. Basic loss per share was USD 0.24 compared to USD 0.33 a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.35 a year ago.

Latest news about Lexaria Bioscience Corp.

Lexaria Bioscience Hires Contract Research Organization For 12-week Study	18/06	MT
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study	18/06	CI
Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study	05/06	CI
Lexaria Bioscience Completes Dosing in Second Round of Semaglutide Formulations Human Pilot Study	05/06	MT
Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise	21/05	MT
Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study	17/05	CI
Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study	08/05	CI
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs	06/05	CI
Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	16/04	MT
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	16/04	CI
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	10/04	CI
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents	02/04	CI
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief	14/03	MT
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	14/03	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	06/03	MT
Sector Update: Health Care	06/03	MT
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise	06/03	MT
Maxim Group Adjusts Lexaria Bioscience Price Target to $12 From $3, Maintains Buy Rating	05/03	MT
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1	05/03	CI
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1	04/03	CI
Lexaria Bioscience Corp. Announces 7% Weight Loss in Animals Supports in its Next 8-Week Animal Study	04/03	CI
Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial	01/03	CI
Lexaria Bioscience Corp. Submits Investigational New Drug Application	30/01	CI
Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program	16/01	CI
Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2023	13/01	CI

Chart Lexaria Bioscience Corp.

Duration

Period

More charts

Company Profile

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Companyâs patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for Lexaria Bioscience Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.64 USD

Average target price

10 USD

Spread / Average Target

+278.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LEXARIA BIOSCIENCE CORP.	+111.20%	3.75Cr
ELI LILLY AND COMPANY	+54.07%	82TCr
NOVO NORDISK A/S	+38.59%	63TCr
JOHNSON & JOHNSON	-7.05%	35TCr
MERCK & CO., INC.	+15.44%	32TCr
ABBVIE INC.	+5.72%	29TCr
ASTRAZENECA PLC	+13.40%	24TCr
ROCHE HOLDING AG	+0.61%	22TCr
NOVARTIS AG	+13.24%	22TCr
AMGEN INC.	+7.42%	17TCr

Other Pharmaceuticals